Extensively Drug-Resistant Tuberculosis: Clinical Trials

9 trials for Extensively Drug-Resistant Tuberculosis, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

8 completed, 1 unknown. 9 Phase 2, 4 Phase 3, 1 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 29Completed 8, Unknown 1
Phase 34Completed 3, Unknown 1
Phase 11Completed 1

Follow Extensively Drug-Resistant Tuberculosis: new trials by email Literature Review of Extensively Drug-Resistant Tuberculosis trials Research Report on Extensively Drug-Resistant Tuberculosis

Trials (filtered) newest first · largest first

All 9 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Trial to Evaluate the Male Reproductive Safety of Pretomanid in Adult Male Participants With Drug Resistant Pulmonary Tuberculosis
Pretomanid, Bedaquiline, moxifloxacin - Tuberculosis, Pulmonary, Tuberculosis, Multidrug-Resistant
Phase 2CompletedGlobal Alliance for TB Drug Development262021-09-162025-01-17
Economic Evaluation of New MDR TB Regimens
Bedaquiline, Pretomanid, Moxifloxacin - Multi-drug Resistant Tuberculosis, Extensively Drug-Resistant Tuberculosis
Phase 2 / Phase 3CompletedMedecins Sans Frontieres, Netherlands732020-10-202024-04-22
PRACTECAL-PKPD Sub Study
Bedaquiline, Pretomanid, Moxifloxacin - Multi-drug Resistant Tuberculosis, Extensively Drug-Resistant Tuberculosis
Phase 2 / Phase 3UnknownMedecins Sans Frontieres, Netherlands2402019-08-062021-05-14
Pragmatic Clinical Trial for a More Effective Concise and Less Toxic MDR-TB Treatment Regimen(s)
Bedaquiline, Pretomanid, Moxifloxacin - Tuberculosis, Multidrug-Resistant, Extensively Drug-Resistant Tuberculosis
Phase 2 / Phase 3CompletedMedecins Sans Frontieres, Netherlands5522017-01-012024-05-01
An Open-label RCT to Evaluate a New Treatment Regimen for Patients With Multi-drug Resistant Tuberculosis
Linezolid, Bedaquiline, Levofloxacin - Tuberculosis, Multidrug Resistant Tuberculosis
Phase 2 / Phase 3CompletedUniversity of Cape Town1542015-11-122021-09-29
Safety and Efficacy of Oral Immunomodulator in Tuberculosis (TB) and TB/HIV Patients
V-5 immunitor - Tuberculosis
Phase 2CompletedLisichansk Regional Tuberculosis Dispensary1232010-01-012012-08-03
TBTC Study 30: Safety and Tolerability of Low Dose Linezolid in MDR TB
Linezolid, Placebo - Multi-drug Resistant Tuberculosis, Extensively Drug Resistant Tuberculosis
Phase 1 / Phase 2CompletedCenters for Disease Control and Prevention362009-04-012026-07-06
Linezolid to Treat Extensively-Drug Resistant Tuberculosis
Immediate Start Linezolid, Delayed Start Linezolid - Pulmonary Tuberculosis, Multidrug Resistant Tuberculosis
Phase 2CompletedNational Institute of Allergy and Infectious Diseases (NIAID)412008-07-012016-03-14
A Trial to Evaluate OPC 67683 in Participants With Pulmonary Sputum Culture-positive, Multidrug-resistant Tuberculosis (TB)
Delamanid, Optimized Background Regimen (OBR), Placebo - Tuberculosis, Pulmonary, Tuberculosis, Multidrug Resistant
Phase 2CompletedOtsuka Pharmaceutical Development & Commercialization, Inc.4812008-05-082021-12-01

Narrower conditions

Tuberculosis, Multidrug-Resistant (9)  ·  Tuberculosis, Pulmonary (6)  ·  Tuberculosis (5)  ·  Anemia (1)  ·  Mycobacterium Infections (1)  ·  Optic Nerve Diseases (1)  ·  Peripheral Nervous System Diseases (1)  ·  Thrombocytopenia (1)

Broader conditions

Actinomycetales Infections (9)  ·  Bacterial Infections (9)  ·  Bacterial Infections and Mycoses (9)  ·  Gram-Positive Bacterial Infections (9)  ·  Infections (9)  ·  Mycobacterium Infections (8)  ·  Lung Diseases (6)  ·  Respiratory Tract Diseases (6)  ·  Respiratory Tract Infections (6)  ·  Tuberculosis (4)  ·  Blood Platelet Disorders (1)  ·  Cranial Nerve Diseases (1)  ·  Cytopenia (1)  ·  Eye Diseases (1)  ·  Hematologic Diseases (1)

Interventions

Linezolid (6)  ·  Moxifloxacin (5)  ·  bedaquiline (5)  ·  pretomanid (4)  ·  Clofazimine (3)  ·  Pyrazinamide (2)  ·  Ethionamide (1)  ·  Isoniazid (1)  ·  Kanamycin (1)  ·  Levofloxacin (1)  ·  OPC-67683 (1)  ·  V-5 immunitor (1)  ·  stearic acid (1)  ·  terizidone (1)

Sponsors

Medecins Sans Frontieres, Netherlands (3)  ·  Centers for Disease Control and Prevention (1)  ·  Global Alliance for TB Drug Development (1)  ·  Lisichansk Regional Tuberculosis Dispensary (1)  ·  National Institute of Allergy and Infectious Diseases (NIAID) (1)  ·  Otsuka Pharmaceutical Development & Commercialization, Inc. (1)  ·  University of Cape Town (1)

Countries

South Africa (6)  ·  Belarus (3)  ·  South Korea (2)  ·  Uzbekistan (2)  ·  China (1)  ·  Egypt (1)  ·  Estonia (1)  ·  Georgia (1)  ·  Japan (1)  ·  Latvia (1)  ·  Peru (1)  ·  Philippines (1)  ·  Ukraine (1)  ·  United States (1)

Top investigators

Antonio Lombardi, MD (1)  ·  Bern Nyang'wa, MB BS, MPH (1)  ·  Bern-Thomas Nyang'wa, MD (1)  ·  Clifton Barry, Ph.D. (1)  ·  Dmytro Butov, MD (1)  ·  Jussi Saukkonen, MD (1)  ·  Keertan Dheda, MBChB (1)  ·  Nesri Padayachin, MBChB (1)  ·  Sedona Sweeny (1)  ·  Waffa El-Sadr, MD (1)

Results publications

PMID 21182457, PMID 22670901, PMID 23075177, PMID 23131255, PMID 27868466, PMID 31932382, PMID 34489274, PMID 35175905, PMID 35698158, PMID 36546625, PMID 37980911, PMID 38842323, PMID 41917253, PMID 42270675